“…The goal of this experiment was to identify chemotypes with exceptional leukemia cell bioactivity. Exceptional activity following treatment with a compound or signaling input can be measured by phospho-flow in different ways, including exceptional potency (i.e., activity at nM or lower concentration) 38 , bioactivity (i.e., orders of magnitude greater responses in a measured proteins; e.g., high per-cell γH2AX indicating exceptionally strong DNA damage response) 16,18,38,39 , pathway selectivity or signature profile (i.e., a specific combination of activities per cell, such as activation of γH2AX without inhibition of p-4EBP1, indicating a DNA damage response without a halt to protein synthesis) 38,39 , and/or exceptional selectivity (i.e., targeting a specific subpopulation of cells, such as targeting cancer cells without targeting healthy cells) 16,38,[40][41][42] . Here, the order of evaluation was first on bioactivity and selectivity, then on profile, and finally on evaluation of potency.…”